<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006683</article-id><article-id pub-id-type="pmc">PMC11860927</article-id><article-id pub-id-type="doi">10.3390/vaccines13020136</article-id><article-id pub-id-type="publisher-id">vaccines-13-00136</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Immunoprotection Provided by Salivary and Intestinal Protein-Based Antigens Against the Ixodid Tick <italic toggle="yes">Amblyomma sculptum</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Natividade</surname><given-names>Ulisses A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00136" ref-type="aff">1</xref><xref rid="fn1-vaccines-13-00136" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Abreu</surname><given-names>Jessica F.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00136" ref-type="aff">1</xref><xref rid="fn1-vaccines-13-00136" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Ribeiro</surname><given-names>Izabela C. T.</given-names></name><xref rid="af1-vaccines-13-00136" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Pereira Filho</surname><given-names>Adalberto A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-13-00136" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Augusto V.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-vaccines-13-00136" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6476-7532</contrib-id><name><surname>Ribeiro</surname><given-names>Helen S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-vaccines-13-00136" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4181-7546</contrib-id><name><surname>Giunchetti</surname><given-names>Rodolfo C.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-vaccines-13-00136" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sant&#x02019;Anna</surname><given-names>Mauricio R. V.</given-names></name><xref rid="af3-vaccines-13-00136" ref-type="aff">3</xref><xref rid="af4-vaccines-13-00136" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Gontijo</surname><given-names>Nelder F.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af3-vaccines-13-00136" ref-type="aff">3</xref><xref rid="af4-vaccines-13-00136" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Marcos H.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af3-vaccines-13-00136" ref-type="aff">3</xref><xref rid="af4-vaccines-13-00136" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1272-4386</contrib-id><name><surname>Araujo</surname><given-names>Ricardo N.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vaccines-13-00136" ref-type="aff">1</xref><xref rid="af4-vaccines-13-00136" ref-type="aff">4</xref><xref rid="c1-vaccines-13-00136" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Matsuyama-Kato</surname><given-names>Ayumi</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Careem</surname><given-names>Faizal</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00136"><label>1</label>Laboratory of Hematophagous Arthropods, Department of Parasitology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil</aff><aff id="af2-vaccines-13-00136"><label>2</label>Laboratory of Cell-Cell Interactions, Department of Morphology, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil</aff><aff id="af3-vaccines-13-00136"><label>3</label>Laboratory of Hematophagous Insects Physiology, Department of Parasitology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil</aff><aff id="af4-vaccines-13-00136"><label>4</label>Instituto Nacional de Ci&#x000ea;ncia e Tecnologia em Entomologia Molecular, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-853, RJ, Brazil</aff><author-notes><corresp id="c1-vaccines-13-00136"><label>*</label>Correspondence: <email>rnaraujo@icb.ufmg.br</email></corresp><fn id="fn1-vaccines-13-00136"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>136</elocation-id><history><date date-type="received"><day>04</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold>&#x000a0;<italic toggle="yes">Amblyomma sculptum</italic> is among the most dangerous ticks in South America, as it is the species most associated with humans and is the main vector of <italic toggle="yes">Rickettsia rickettsii</italic>. In the face of the problems related to tick control based on chemical acaricides, vaccines emerge as a promising method. In previous works, three salivary recombinant proteins (rAs8.9kDa, rAsKunitz, and rAsBasicTail) and one protein based on intestinal immunogenic regions (rAsChimera) were described with 59 to 92% vaccine efficacy against <italic toggle="yes">A. sculptum</italic> females. Here, we evaluate novel vaccine formulations containing binary or multiple combinations of the antigens rAs8.9kDa, rAsKunitz, rAsBasicTail, and rAsChimera against the three instars of the tick. <bold>Methods:</bold> A control group of mice was immunized with adjuvant alone (aluminum hydroxide gel) and compared to five groups immunized with formulations containing two, three, or four of the antigens. <bold>Results:</bold> The formulations were safe, with no significant alterations to host behavior and hematological or biochemical parameters. Immunizations induced a significant increase in the CD19<sup>+</sup> B lymphocyte percentage in all groups, but no difference was seen for CD8<sup>+</sup> and CD4<sup>+</sup> T lymphocytes or CD14<sup>+</sup> monocytes. The best protection was observed for the formulations containing two antigens, which reached above 98% efficacy, while the groups containing three or four antigens presented 92.7 and 94.4% efficacy, respectively. <bold>Conclusions:</bold> All antigen combinations were promising as vaccine formulations against <italic toggle="yes">A. sculptum</italic>. The formulation containing rAs8.9kDa and rAsChimera showed the best efficacy and should be focused on in further experiments.</p></abstract><kwd-group><kwd>anti-tick vaccine</kwd><kwd>tick control</kwd><kwd>saliva</kwd><kwd>intestine</kwd><kwd>immune response</kwd><kwd>vaccine efficacy</kwd></kwd-group><funding-group><award-group><funding-source>Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de Minas Gerais (FAPEMIG)</funding-source></award-group><award-group><funding-source>Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPq)</funding-source></award-group><award-group><funding-source>Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior (CAPES)</funding-source></award-group><award-group><funding-source>Instituto Nacional de Ci&#x000ea;ncia e Tecnologia em Entomologia Molecular (INCT-EM)</funding-source></award-group><funding-statement>This research was funded by the Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPq), Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior (CAPES), and the Instituto Nacional de Ci&#x000ea;ncia e Tecnologia em Entomologia Molecular (INCT-EM).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00136"><title>1. Introduction</title><p><italic toggle="yes">Amblyomma cajennense sensu lato</italic> ticks have a wide distribution across the American continent, spanning from the southern United States to northern Argentina [<xref rid="B1-vaccines-13-00136" ref-type="bibr">1</xref>]. Among the six species of the complex, <italic toggle="yes">Amblyomma sculptum</italic> Berlese, 1888 is the most important in South America, as it is found in the most populated areas, is the primary tick associated with humans [<xref rid="B2-vaccines-13-00136" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00136" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00136" ref-type="bibr">4</xref>], and is the main vector of the bacteria <italic toggle="yes">Rickettsia rickettsii</italic>, the causative agent of the Brazilian spotted fever [<xref rid="B5-vaccines-13-00136" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-13-00136" ref-type="bibr">6</xref>]. The species has been reported in Argentina, Bolivia, Brazil, and Paraguay, mainly associated with the biomes in Cerrado and the degraded areas of the Atlantic rainforest [<xref rid="B3-vaccines-13-00136" ref-type="bibr">3</xref>]. Horses, capybaras, and tapirs are among the primary hosts of <italic toggle="yes">A. sculptum</italic>, but several other domestic and wild species of hosts, including mammals, birds, and reptiles, have been found parasitized, especially by immature instars, which are considered to have low host specificity [<xref rid="B7-vaccines-13-00136" ref-type="bibr">7</xref>]. Additionally, <italic toggle="yes">A. sculptum</italic> is associated with most of the human cases of Brazilian spotted fever, caused by the bacteria <italic toggle="yes">Rickettsia rickettsii</italic> [<xref rid="B5-vaccines-13-00136" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-13-00136" ref-type="bibr">6</xref>]. The bacteria can be transmitted by any of its instars due to the occurrence of transovarial transmission [<xref rid="B8-vaccines-13-00136" ref-type="bibr">8</xref>].</p><p>Tick control is still mainly based on chemical acaricides [<xref rid="B9-vaccines-13-00136" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-13-00136" ref-type="bibr">10</xref>], a method that has aroused concerns due to the possibility of contaminating the environment, products of animal origin, and workers dealing with animals [<xref rid="B11-vaccines-13-00136" ref-type="bibr">11</xref>]. The use of acaricides can also select resistant tick populations, and this concern is also shared for <italic toggle="yes">A. sculptum</italic> [<xref rid="B12-vaccines-13-00136" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00136" ref-type="bibr">13</xref>].</p><p>Developing novel and more efficient ways to control <italic toggle="yes">A. sculptum</italic> may help solve or minimize the problems generated by chemical acaricide treatments. Anti-tick vaccines are suitable alternatives, as they are more environmentally friendly and may be used alone or combined with acaricides or other control methods. The use of vaccines may contribute significantly to the reduction of ticks on hosts and also in the environment, thus reducing the occurrence of diseases caused by tick-borne pathogens.</p><p>Few studies have been carried out to identify antigens and develop vaccines against ticks of the <italic toggle="yes">A. cajennense</italic> complex. The BM86 antigen, the basis of commercial vaccines against the cattle tick <italic toggle="yes">Rhipicephalus microplus</italic>, was found to be ineffective against <italic toggle="yes">A. cajennense s. l.</italic> [<xref rid="B14-vaccines-13-00136" ref-type="bibr">14</xref>], while the P0 antigen, initially also isolated from <italic toggle="yes">R. microplus</italic>, demonstrated 56% efficacy against <italic toggle="yes">A. mixtrum</italic>, another species of the <italic toggle="yes">A. cajennense</italic> complex [<xref rid="B15-vaccines-13-00136" ref-type="bibr">15</xref>]. Additionally, proteins associated with apoptosis inhibition were investigated as possible targets against <italic toggle="yes">A. sculptum</italic> using RNA interference, showing promising results as potential vaccine candidates, but vaccination trials still need to be carried out [<xref rid="B16-vaccines-13-00136" ref-type="bibr">16</xref>]. Recently, Costa et al. [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>] identified three multifunctional <italic toggle="yes">A. sculptum</italic> salivary proteins, named AsKunitz, As8.9kDa and AsBasicTail. In vaccination trials conducted on mice, these proteins demonstrated efficacies of 85.3, 92.8, and 59.4% against female ticks. Furthermore, a chimeric recombinant protein constructed from a sequence of 22 immunogenic regions from gut molecules (named rAsChimera) showed an efficacy of 80.8% against females [<xref rid="B18-vaccines-13-00136" ref-type="bibr">18</xref>].</p><p>The possibility of creating anti-tick vaccines has been explored since earlier studies of tick infestation showed that hosts can acquire effective immune responses against ticks after initial parasitism, as is commonly seen for several <italic toggle="yes">Bos indicus</italic> breeds [<xref rid="B19-vaccines-13-00136" ref-type="bibr">19</xref>]. Studies on the BM86 antigen have shown that antibodies play an important role in the protection, either by IgG alone or with the aid of the complement system of the host. Antibodies induce damage to the gut epithelium, reducing tick viability, hematophagy capacity, and reproductive performance [<xref rid="B20-vaccines-13-00136" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-13-00136" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00136" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-13-00136" ref-type="bibr">23</xref>]. Therefore, the present work explores the hypothesis that enhancing the attack on the gut epithelium by the host complement system may lead to higher efficacies of anti-tick vaccines. For this, the present work describes the results of vaccine trials using formulations containing binary (rAs8.9kDa and rAsChimera, rAsBasicTail and rAsChimera, or rAsKunitz and rAsChimera) or multiple (rAs8.9kDa, rAsKunitz, and rAsChimera or rAs8.9kDa, rAsKunitz, rAsBasicTail, and rAsChimera) combinations of antigens based on gut surface and anti-complement proteins [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00136" ref-type="bibr">18</xref>], detailing the vaccines&#x02019; safety, immunological assessments, and the effect on the parameters used to calculate vaccine efficacy.</p></sec><sec id="sec2-vaccines-13-00136"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-13-00136"><title>2.1. Experimental Ticks and Ethical Statement</title><p>Ticks used in the experiments were obtained from an <italic toggle="yes">A. sculptum</italic> colony kept at the Laboratory of Hematophagous Arthropods, UFMG. Ticks were maintained in a BOD incubator under controlled conditions of temperature (28 &#x000b1; 2 &#x000b0;C) and humidity (85 &#x000b1; 5%), and were fed on Swiss mice using feeding chambers according to the methodology described by Bouchard and Wikel [<xref rid="B24-vaccines-13-00136" ref-type="bibr">24</xref>]. All ticks used were aged between 20 and 40 days after hatching or molting. The Ethics Committee on the Use of Animals at the Universidade Federal de Minas Gerais (CEUA/UFMG) approved the maintenance of our tick colony and the vaccine experiments (protocols 06/2020 and 103/2017).</p></sec><sec id="sec2dot2-vaccines-13-00136"><title>2.2. Vaccine Formulations and Experimental Groups</title><p>Four recombinant antigens identified in previous works were evaluated in the vaccine trials: rAs8.9kDa&#x02014;a 13 kDa protein containing a von Willebrand factor (vWF)-type C domain; rAsKunitz&#x02014;a 10.9 kDa protein containing a Kunitz_BPTI-type domain; rAsBasictail&#x02014;an 18.9 kDa protein that contains several lysine residues in the carboxy-terminal region; and rAsChimera&#x02014;a 48.5 kDa protein that contains 22 immunogenic regions similar to those found in the seven intestinal proteins of <italic toggle="yes">A. sculptum</italic> [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00136" ref-type="bibr">18</xref>]. The sequence of each antigen and the production of the recombinant proteins in <italic toggle="yes">Escherichia coli</italic> BL21 were previously described [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00136" ref-type="bibr">18</xref>]. Briefly, sequences were cloned into pET28a-TEV vectors and transformed into bacteria by heat shock. Purification was carried out using His Trap<sup>&#x000ae;</sup> Hp affinity columns (GE Healthcare Life Sciences, Chicago, IL, USA) followed by performing affinity chromatography with an AKTA-prime plus<sup>&#x000ae;</sup> (GE Healthcare Life Sciences). The samples were evaluated using SDS-PAGE and had their protein content measured [<xref rid="B25-vaccines-13-00136" ref-type="bibr">25</xref>]. Expression of the recombinants was confirmed by western blotting and plasmid sequencing.</p><p>The recombinants were used to produce five vaccine formulations containing five &#x000b5;g of each protein and 0.1 mg of aluminum hydroxide gel (Sigma&#x02013;Aldrich, St. Louis, MO, USA.) as an adjuvant, which was dissolved in a final volume of 100 &#x000b5;L of sterile PBS (137 mM NaCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, 2.7 mM KCl, pH 7.4). The vaccinated groups and the recombinant proteins used in each of the formulations were: V1&#x02014;rAs8.9kDa and rAsChimera, V2&#x02014;rAsBasicTail and rAsChimera, V3&#x02014;rAsKunitz and rAsChimera, V4&#x02014;rAs8.9kDa, rAsKunitz and rAsChimera, and V5&#x02014;rAs8.9kDa, rAsKunitz, rAsBasicTail, and rAsChimera. The control group (Ct) was injected with 0.1 mg of adjuvant (aluminum hydroxide gel) in PBS. The vaccinated groups were challenged with larvae, nymphs, and adult couples (one female and one male) of <italic toggle="yes">A. sculptum</italic>.</p></sec><sec id="sec2dot3-vaccines-13-00136"><title>2.3. Immunization of the Experimental Groups</title><p>The vaccination experiments were performed using 4-to-6-week-old male Swiss mice obtained at the UFMG&#x02019;s Bioterism Centerterism (CEBio). The animals were maintained in a 12:12-hour light&#x02013;dark cycle and received rodent food and water ad libitum. Three doses of the formulations were applied to each animal subcutaneously on the animal&#x02019;s back at 14-day intervals (<xref rid="vaccines-13-00136-f001" ref-type="fig">Figure 1</xref>). Individual blood samples were collected by puncturing the caudal lateral vein two days before immunizations (D-2) and at different times after vaccination had started, up until day 262 (D262) (<xref rid="vaccines-13-00136-f001" ref-type="fig">Figure 1</xref>). Three sets of mouse groups were used and challenged with each tick instar. Groups challenged with larvae and nymphs contained five mice each, while ten mice were used for groups of adults. Ticks that fed on animals that died or showed any health or behavioral alterations during the challenge were removed from the analysis.</p></sec><sec id="sec2dot4-vaccines-13-00136"><title>2.4. Behavioral Analysis and Immunobiological Safety</title><p>Vaccination safety was clinically assessed by macroscopic analysis of the inoculation site to check for the presence of nodules or wounds within 72 h following each injection. In addition, the animals&#x02019; behavior was checked daily to identify any possible alterations.</p><p>Immunobiological safety was also assessed by checking the hematological and serum biochemical parameters on D-2 and day 40 (D40) of five animals in each group. This involved collecting approximately 50 &#x003bc;L of blood in 0.5 mL tubes containing EDTA (Vacuplast, Cotia, SP, Brazil), which was then used for erythrocytic series measurements (erythrocytes, hemoglobin, and hematocrit) and total leukocytes measurements using an Abacus Analyzer (Celer Biotecnologia, Belo Horizonte, MG, Bazil). The biochemical profile (urea, creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT)) was also evaluated. For this, approximately 50 &#x003bc;L of blood was collected in a 1.5 mL microcentrifuge tube, which was kept resting in room temperature for 30 min, was centrifuged at 600&#x000d7; <italic toggle="yes">g</italic> for 10 min, and then the entire serum volume was collected and analyzed using a Cobas Mira Biochemical Analyzer (Roche, Basel, Switzerland).</p></sec><sec id="sec2dot5-vaccines-13-00136"><title>2.5. Phenotypic Profile of the Lymphocyte Populations</title><p>The lymphocyte phenotypic profile of the immunized animals was evaluated by flow cytometry using blood collected from five animals in each group. Aliquots containing 50 &#x000b5;L of mouse blood were transferred to 5 mL polystyrene tubes (BD Falcon round-bottom polystyrene tubes) containing 20 &#x000b5;L of anti-CD3-Percep-Cy5 antibodies (clone 145-2C11, eBioscience, Thermo Fisher Scientific), anti-CD4-FITC (clone RM4-5, eBioscience, Thermo Fisher Scientific, Waltham, MA, USA), and anti-CD8-APC (clone 53-6.7, eBioscience, Thermo Fisher Scientific). An additional 50 &#x003bc;L was transferred to a polystyrene tube containing the anti-CD19-FITC antibody (clone MB19-1, eBioscience, Thermo Fisher Scientific), and an extra 50 &#x003bc;L was transferred to a polystyrene tube containing the anti-CD14-APC antibody (clone Sa2-8, eBioscience, Thermo Fisher Scientific). The tubes were homogenized by vortexing and incubated for 30 min in the dark. After incubation, 2 mL (1 mL at a time) of Billing Dog solution (Facs lysing solution, Becton Dickinson) was added to the vortex and incubated for 10 min in the dark. After incubation, the lysis reaction was stopped by adding 1 mL of PBS wash (PBS containing 0.5% bovine serum albumin (BSA) and 0.1% sodium azide, pH 7.2), and samples were centrifuged at 600&#x000d7; <italic toggle="yes">g</italic> for 7 min at 18 &#x000b0;C. After centrifugation, the supernatant was discarded, and the pellet was washed using 2 mL of PBS-wash. The pellet was then resuspended in 200 &#x003bc;L of Macs Facs Fix fixative solution (10.0 g/L paraformaldehyde, 10.2 g/L sodium cacodylate, and 6.65 g/L sodium chloride) for reading on a FACSCalibur flow cytometer (Becton Dickinson) with acquisition of 30,000 events/tube. The software FlowJo 10.4 (Tree Star) was used to analyze cellular immunophenotyping. Total lymphocytes were identified by gating on the FSC versus SSC plot (<xref rid="app1-vaccines-13-00136" ref-type="app">Supplementary Materials&#x02014;Figure S1A</xref>). CD4<sup>+</sup> and CD8<sup>+</sup> T cells were selected based on their co-expression with the CD3 T cell marker (CD4<sup>+</sup>CD3<sup>+</sup> and CD8<sup>+</sup>CD3<sup>+</sup>, respectively) within the total lymphocytes gate (<xref rid="app1-vaccines-13-00136" ref-type="app">Supplementary Materials&#x02014;Figure S1B,C</xref>). B cells were identified as CD19<sup>+</sup> cells within the total lymphocyte gate (<xref rid="app1-vaccines-13-00136" ref-type="app">Supplementary Materials&#x02014;Figure S1D</xref>). The results for CD4<sup>+</sup>CD3<sup>+</sup>, CD8<sup>+</sup>CD3<sup>+</sup>, and CD19<sup>+</sup> were expressed as percentages of positive cells within the total lymphocyte gate. Monocytes were characterized by CD14<sup>+</sup> expression and intermediate granularity (<xref rid="app1-vaccines-13-00136" ref-type="app">Supplementary Materials&#x02014;Figure S1E</xref>).</p></sec><sec id="sec2dot6-vaccines-13-00136"><title>2.6. Humoral Response</title><p>To evaluate the production of antigen-specific antibodies, 50 &#x000b5;L of individual blood samples were collected from 13 animals of each group and the serum was obtained as described above. Antigen-specific IgG levels for each of the vaccine targets were determined individually in the hosts&#x02019; serum through enzyme-linked immunosorbent assays (ELISAs) using 0.5 &#x003bc;g of each purified antigen in 50 &#x003bc;L of carbonate buffer/well in 96-well ELISA plates (COSTAR<sup>&#x000ae;</sup> 3590 high binding). After incubation at 4 &#x000b0;C in a humid chamber overnight, the plates were washed and blocked for 2 h at 37 &#x000b0;C with agitation with a blocking solution (PBS containing 2% casein). After three washes with PBS-Tween (PBS with 0.05% Tween 20), the plates were incubated for 1 h with shaking at 37 &#x000b0;C and with sera at a 1:320 dilution in PBS-Tween, and after further washing, incubated with anti-mouse IgG conjugated to peroxidase (Sigma&#x02013;Aldrich<sup>&#x000ae;</sup>) at a 1:10,000 dilution with PBS-Tween. Results were visualized using 100 mM of phosphate&#x02013;citrate buffer (pH 5.0) that contained 0.025% H<sub>2</sub>O<sub>2</sub> and 0.01% o-phenylenediamine. Reactions were stopped with the addition of 200 &#x003bc;L of 12.5% H<sub>2</sub>SO<sub>4</sub>, and the absorbance was measured at 492 nm in an ELISA reader (VERSAmax<sup>&#x000ae;</sup>, Molecular Devises, San Jose, CA, USA) with the SoftMax<sup>&#x000ae;</sup> pro 3.0 software (Molecular Devices).</p></sec><sec id="sec2dot7-vaccines-13-00136"><title>2.7. Tick Challenge and Assessment of Efficacy</title><p>The tick challenge was performed 15 days after the last immunization (day 43). Each mouse was infested with 50 larvae, 10 nymphs, or one male and one female using feeding chambers [<xref rid="B24-vaccines-13-00136" ref-type="bibr">24</xref>]. Several feeding and development parameters were measured, such as feeding period, final weight, percentage of feeding, percentage of molt, and mortality. Female reproductive parameters, such as fertile females (females that laid eggs), egg mass, and larvae hatching, were also evaluated. Vaccine efficacy, considering the parameters assessed from larvae, nymphs, and females, was calculated according to Aguirre et al. [<xref rid="B26-vaccines-13-00136" ref-type="bibr">26</xref>] using the formula E(%) = 100 &#x000d7; [1 &#x02212; (RL &#x000d7; VL &#x000d7; RN &#x000d7; VN &#x000d7; RA &#x000d7; OA &#x000d7; FE)] where: RL is the effect of vaccination on larvae recovery = RLvaccinated/RLcontrol; RN is the effect of vaccination on nymph recovery = RNv/RNc; RA is the effect of vaccination on adult female recovery = RAv/Rac; VL is the effect on larvae viability = VLv/VLc; VN is the effect on nymph viability = VNv/VNc; OA is the effect on female oviposition, which is the ratio between the average weight of the egg mass laid by females in the vaccinated (OAv) and control (OAc) groups = OAv/OAc; and FE is the effect on egg fertility, which is the ratio between the average hatchability (%) of eggs laid by females in the vaccinated (FEv) and control (FEc) groups = FEv/FEc.</p></sec><sec id="sec2dot8-vaccines-13-00136"><title>2.8. Statistical Analysis</title><p>Data were transferred to GraphPad Prism 7.0 software for statistical analysis. Data are represented by means &#x000b1; standard errors or means &#x000b1; standard deviations, and each tick was considered as one individual replicate. Data normality was assessed using the Kolmogorov&#x02013;Smirnov test. The analysis of variance (ANOVA) test was performed for data with a normal distribution, followed by Tukey&#x02019;s or Dunnett&#x02019;s post-test. Non-normally distributed data were analyzed using the Kruskal&#x02013;Wallis test and Dunn&#x02019;s post-test. The significance level considered was <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00136"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00136"><title>3.1. Immunobiological Safety and Harm Analysis</title><p>Immunizations induced no adverse reactions in mice in the experimental groups. No nodules, papules, or ulcers were seen at the inoculum sites, and no animal behavioral changes were observed. Biochemical and hematological parameters were assessed in all experimental groups at D-2 and D40, and no major alterations that indicated an impact on homeostasis were induced by the vaccinations (<xref rid="app1-vaccines-13-00136" ref-type="app">Supplementary Materials&#x02014;Tables S1 and S2</xref>). The alterations observed were a significant increase (<italic toggle="yes">p</italic> &#x0003c; 0.05) between D-2 and D40 in the AST levels of groups V1, V2, and V5, and a significant decrease (<italic toggle="yes">p</italic> &#x0003c; 0.05) in MCHC levels in group V3.</p></sec><sec id="sec3dot2-vaccines-13-00136"><title>3.2. Leukocyte Immunophenotyping</title><p>Analysis of leucocytes from experimental mice showed no significant differences (<italic toggle="yes">p</italic> &#x0003e; 0.05) in CD4<sup>+</sup> T cells and CD14<sup>+</sup> monocytes between D-2 and D40 or between control and vaccinated groups at D40 (<xref rid="vaccines-13-00136-f002" ref-type="fig">Figure 2</xref>A,C). The percentage of CD8<sup>+</sup> T cells was similar (<italic toggle="yes">p</italic> &#x0003e; 0.05) for all comparisons, except for a significant decrease (<italic toggle="yes">p</italic> &#x0003c; 0.05) seen in group V5 at D40 in comparison to D-2 (<xref rid="vaccines-13-00136-f002" ref-type="fig">Figure 2</xref>B).</p><p>CD19<sup>+</sup> B cells were affected by the immunizations. All groups saw significant increases (<italic toggle="yes">p</italic> &#x0003c; 0.05) in the percentage of CD19<sup>+</sup> B cells from D-2 to D40. There were significant differences (<italic toggle="yes">p</italic> &#x0003c; 0.05) between groups at day 40, as groups V4 and V5 had a significantly higher (<italic toggle="yes">p</italic> &#x0003c; 0.05) percentage of cells in comparison to controls, while group V2 had a significantly lower percentage of cells in comparison to V3, V4, and V5 (<xref rid="vaccines-13-00136-f002" ref-type="fig">Figure 2</xref>D).</p></sec><sec id="sec3dot3-vaccines-13-00136"><title>3.3. Humoral Response</title><p>The antigen-specific IgG levels significantly increased in all vaccinated groups after immunizations. Overall, IgG levels were significantly higher on D26 (after the second immunization) and reached a peak on D41 (after the third immunization), followed by a gradual reduction until the end of the experiment (<xref rid="vaccines-13-00136-f003" ref-type="fig">Figure 3</xref> and <xref rid="vaccines-13-00136-f004" ref-type="fig">Figure 4</xref>).</p><p>When the IgG levels against all four antigens were analyzed together, the profiles and levels were relatively similar between groups V1&#x02013;4, while group V5 had significantly lower IgG levels throughout the whole experimental period (<xref rid="vaccines-13-00136-f003" ref-type="fig">Figure 3</xref>). </p><p>Analysis of the IgG levels against each antigen confirmed that the formulation used in V5 induced lower IgG levels against all four antigens (<xref rid="vaccines-13-00136-f004" ref-type="fig">Figure 4</xref>). Concerning the other groups, overall results showed that rAs8.9kDa had the higher antiserum-specific IgG levels (<xref rid="vaccines-13-00136-f004" ref-type="fig">Figure 4</xref>B), followed by rAsChimera (<xref rid="vaccines-13-00136-f004" ref-type="fig">Figure 4</xref>D) and rAsBasicTail (<xref rid="vaccines-13-00136-f004" ref-type="fig">Figure 4</xref>C), while rAsKunitz had the lowest levels, which were, nevertheless, significantly (<italic toggle="yes">p</italic> &#x0003c; 0.05) higher than the control&#x02019;s (<xref rid="vaccines-13-00136-f004" ref-type="fig">Figure 4</xref>A). Interestingly, rAs8.9kDa antiserum levels remained higher until D262 in groups V1 and V4, while specific IgG levels decreased earlier for all other antigens (<xref rid="vaccines-13-00136-f004" ref-type="fig">Figure 4</xref>).</p></sec><sec id="sec3dot4-vaccines-13-00136"><title>3.4. Tick Challenge on Immunized Mice</title><p>The study revealed that the three tick instars had some parameters affected when fed on immunized mice. In general, molting was the most impacted parameter of immature instars, while females experienced fertility-related effects (<xref rid="vaccines-13-00136-t001" ref-type="table">Table 1</xref> and <xref rid="vaccines-13-00136-f005" ref-type="fig">Figure 5</xref> and <xref rid="vaccines-13-00136-f006" ref-type="fig">Figure 6</xref>). Upon detailed evaluation, larvae showed no issues in feeding on immunized mice (<xref rid="vaccines-13-00136-f005" ref-type="fig">Figure 5</xref>A), but ticks from groups V2 and V3 had significantly (<italic toggle="yes">p</italic> &#x0003c; 0.05) lower final weights in comparison to controls (<xref rid="vaccines-13-00136-f005" ref-type="fig">Figure 5</xref>D). The most considerable differences were observed in larvae recovery and molting, with the percentage of larvae able to feed and reach the nymph instar being less than 15% in groups V1, V2, and V3 (<xref rid="vaccines-13-00136-t001" ref-type="table">Table 1</xref>).</p><p>For nymphs, the feeding period was also not affected by immunizations (<xref rid="vaccines-13-00136-f005" ref-type="fig">Figure 5</xref>B); however, the final weight was significantly reduced in groups V1 and V4 (<xref rid="vaccines-13-00136-f005" ref-type="fig">Figure 5</xref>E), and molt was reduced to less than 20% in groups V1, V2, and V3 (<xref rid="vaccines-13-00136-t001" ref-type="table">Table 1</xref>). Similar to larvae, groups V1 and V3 were the most affected, as total mortality was higher than 80% for V2 and V3, and 92% for V1 (<xref rid="vaccines-13-00136-t001" ref-type="table">Table 1</xref>).</p><p>During the adult challenge, two mice died (from groups V1 and V2) and their data were removed from the analysis. Female ticks had no significant differences (<italic toggle="yes">p</italic> &#x0003e; 0.05) compared to the controls in their feeding period and final weight (<xref rid="vaccines-13-00136-f005" ref-type="fig">Figure 5</xref>C,F), as well as in the egg mass (<xref rid="vaccines-13-00136-f006" ref-type="fig">Figure 6</xref>A) and percent of hatching larvae (<xref rid="vaccines-13-00136-f006" ref-type="fig">Figure 6</xref>B). However, the percentage of fed females was reduced, mainly in groups V3 and V4, as well as the percentage of fertile females in groups V3 and V5 (<xref rid="vaccines-13-00136-t001" ref-type="table">Table 1</xref>).</p><p>The feeding and development parameters of all the instars, along with the female reproductive parameters, were used to calculate the overall efficacies of each vaccine formulation compared to the control. Three of the four formulations had an efficacy higher than 90%, with the best results observed in groups V1 and V3, whose efficacies were higher than 99% (<xref rid="vaccines-13-00136-t002" ref-type="table">Table 2</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00136"><title>4. Discussion</title><p>The present work is part of a series of studies conducted by Costa et al. [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00136" ref-type="bibr">18</xref>], and adds novel information to the search for a vaccine against the tick <italic toggle="yes">A. sculptum</italic>. Novel formulations using the antigens rAsKunitz, rAs8.9kDa, rAsBasicTail, and rAsChimera were tested, and additional aspects of the immune response induced by immunizations were assessed, as well as the safety of the inoculums and the leukocyte phenotypes. Also, the tick challenge was carried out with all three tick instars used for efficacy calculations. The results confirmed the potential of the proteins rAs8.9kDa, rAsKunitz, rAsBasicTail, and rAsChimera to become antigens against <italic toggle="yes">A. sculptum</italic>.</p><p>The vaccine formulations were constructed based on the possible mechanism of action previously described for the <italic toggle="yes">R. microplus</italic> intestinal hidden antigen BM86, where protection from ticks was correlated with the level of antibodies against midgut membrane antigens and the lytic effect caused by the host&#x02019;s blood complement system [<xref rid="B20-vaccines-13-00136" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-13-00136" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00136" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-13-00136" ref-type="bibr">23</xref>]. As the three salivary antigens used in the present work are inhibitors of the complement system [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>], we hypothesize that anti-rAsChimera antibodies could activate the classical pathway of the host&#x02019;s blood complement system by binding to epitopes of proteins on the intestinal epithelium&#x02019;s surface, and antibodies against these salivary proteins would prevent the complement inhibition promoted by those molecules. Those antibody features would induce a strong complement attack on the tick&#x02019;s gut epithelium. Therefore, all vaccine formulations contained an antigen based on intestinal immunogenic regions (rAsChimera) plus one, two, or three salivary antigens.</p><p>For insects, complement inhibition at the intestinal level is important to avoid damage to the epithelium [<xref rid="B27-vaccines-13-00136" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-13-00136" ref-type="bibr">28</xref>], and a similar phenomenon may occur with ticks. The effector mechanisms of the formulations tested here still need to be elucidated, but the data on high mortality in immature stages before molting (<xref rid="vaccines-13-00136-t001" ref-type="table">Table 1</xref>) is compatible with our hypothesis, which involves antibodies and the complement system.</p><p>Vaccine formulations were safe, as no toxic effects were seen on the immunized animals either at the injection site or in the liver or kidney physiology. Hematological parameters were also not altered. This is an expected result, as the formulations do not contain any potentially harmful components. In addition, the adjuvant used was an aluminum compound, which is considered safe and has been used in humans and animals for several years [<xref rid="B29-vaccines-13-00136" ref-type="bibr">29</xref>].</p><p>Induction of the immune response was seen in all immunized groups. The leukocyte phenotyping showed that B cells had the most marked difference of the cell types analyzed, showing greater proliferation. However, the presence of the adjuvant was crucial since the control group also showed an increase from D-2 to D40, an expected effect of aluminum hydroxide [<xref rid="B29-vaccines-13-00136" ref-type="bibr">29</xref>]. A similarity in monocyte and CD3<sup>+</sup> cells&#x02019; circulating levels was observed in a previous anti-tick vaccine trial [<xref rid="B30-vaccines-13-00136" ref-type="bibr">30</xref>] and is in line with an expected, more intense anti-tick immune response at the bite site instead of at the circulation level [<xref rid="B31-vaccines-13-00136" ref-type="bibr">31</xref>].</p><p>The most positive parameter of the immunizations was the increased IgG levels, an extremely desired response in anti-tick vaccines [<xref rid="B20-vaccines-13-00136" ref-type="bibr">20</xref>]. The inoculants given to all groups induced increased antigen-specific IgG levels, although some responded better than others. The IgG increase varied from about ninefold for anti-rAs8.9kDa IgG in group V4 to about threefold for anti-rKunitz IgG in group V3.</p><p>Overall, groups that contained the rAs8.9kDa antigen had the highest and longest-lasting IgG levels (<xref rid="vaccines-13-00136-f004" ref-type="fig">Figure 4</xref>B), corroborating previous work that used the same antigen [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>]. It is of note that group V4 had the earliest humoral response, with significantly higher antigen-specific IgG levels before the second immunization. The reason for such an increase remains unclear and should be further investigated. On the other hand, group V5 contained rAs8.9kDa in the formulation and showed the lowest antiserum IgG results. The amount of antigens in this formulation (20 &#x000b5;g/inoculum) impaired the higher elevation of antigen-specific IgG levels, which were significantly higher than controls only on D41. Indeed, the reduction in the production of specific antibodies with different antigen combinations has been discussed in the literature and may be a consequence of antigenic competition and immunotolerance, among other possibilities [<xref rid="B32-vaccines-13-00136" ref-type="bibr">32</xref>]. It is also of note that bacterial contaminants could have been present in the inoculums, as the recombinant proteins were produced in <italic toggle="yes">E. coli</italic>, and the presence of even low amounts of LPS or other bacterial contaminants could have influenced the antigen-specific humoral and cellular responses [<xref rid="B33-vaccines-13-00136" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-13-00136" ref-type="bibr">34</xref>]. Such an occurrence could have impaired a higher IgG response in all groups, a possibility that is in line with the results from the V5 group, which was the one that contained the higher amounts of recombinants in the inoculum.</p><p>Notably, significantly higher IgG levels than controls were seen for most groups and proteins until D262. The inoculums were responsible for the increased IgG levels, but tick salivation during feeding can also induce specific antibody production [<xref rid="B35-vaccines-13-00136" ref-type="bibr">35</xref>]. The sequences of rAsKunitz, rAsBasicTail, and rAs8.9kDa are based on salivary exposed proteins, so tick feeding during the challenge may have helped maintain the specific IgG levels higher for extended periods. On the other hand, rAsChimera is based on concealed intestinal immunogenic regions, and no antigenic boost during feeding was expected [<xref rid="B36-vaccines-13-00136" ref-type="bibr">36</xref>]. Therefore, the results indicate that the inoculum stimulus alone was sufficient to maintain higher anti-rAsChimera IgG levels until D262 in groups V1 and V4.</p><p>The tick challenge showed that feeding time was not affected by immunizations, but the volume of blood ingested was reduced for larvae and nymphs. Other affected parameters were the number of ticks that completed feeding (especially for larvae and females), molting time, and female fertility. Those parameters contributed to overall vaccine efficacy, which was above 90% in three of the four groups and above 99% in three. Those efficacies were equivalent to the ones observed for the antigens rAsKunitz, rAsBasicTail, rAs8.9kDa, and rAsChimera, which achieved 59 to 92% against females and up to 100% against nymphs [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00136" ref-type="bibr">18</xref>]. Efficacies were also higher than in other works that tested antigens against <italic toggle="yes">A. cajennense s.l.</italic>, where a BM86 formulation had no efficacy at all [<xref rid="B14-vaccines-13-00136" ref-type="bibr">14</xref>], and the P0 antigen was only 54% effective against <italic toggle="yes">A. mixtrum</italic> [<xref rid="B15-vaccines-13-00136" ref-type="bibr">15</xref>]. However, it is of note that the efficacy of the present work was calculated according to Aguirre et al. [<xref rid="B26-vaccines-13-00136" ref-type="bibr">26</xref>], which describes a formula used for three host ticks, applied here due to the challenges performed with all three tick instars. On the other hand, the efficacy of previous works with <italic toggle="yes">A. cajennense s.l.</italic> was calculated based only on adult challenges and used a formula adapted from one host tick [<xref rid="B37-vaccines-13-00136" ref-type="bibr">37</xref>] that considered only female data.</p><p>Thus, the results obtained in the present work, together with previous findings [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00136" ref-type="bibr">18</xref>], are encouraging and suggest that further studies should focus on the combination of rAs8.9kDa with rAsChimera. To do this, those studies should provide a better characterization of the immune response induced by vaccination, especially if the protective response is indeed dependent on complement activation in the gut environment. If this is the case, the focus should be on the production of antibody subtypes that trigger the classical pathway of the complement system [<xref rid="B38-vaccines-13-00136" ref-type="bibr">38</xref>], whose levels should be measured and for which novel means of elevation should be developed. Also, further studies should test antigen protection in natural hosts, as efficacies obtained in laboratory models can be as high as 99% [<xref rid="B39-vaccines-13-00136" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00136" ref-type="bibr">40</xref>] but are normally less effective when tests are carried out with natural hosts [<xref rid="B41-vaccines-13-00136" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-13-00136" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00136" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00136" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-13-00136" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00136" ref-type="bibr">46</xref>]. For <italic toggle="yes">A. sculptum</italic>, the main targets are horses and capybaras, which are considered the primary domestic and wild hosts, respectively, and have been implicated as tick maintainers in most of the areas of reported transmission of <italic toggle="yes">R. rickettsii</italic> in Southeast Brazil [<xref rid="B6-vaccines-13-00136" ref-type="bibr">6</xref>]. As <italic toggle="yes">A. sculptum</italic> is a seasonal tick that needs one year to complete one generation in the natural environment [<xref rid="B7-vaccines-13-00136" ref-type="bibr">7</xref>], if the vaccine efficacies observed here are repeated in the natural hosts, a few years of vaccination would be enough to achieve effective environmental population control. This strategy would be advantageous for tick control in horses and capybaras, for which management imposes a significant impairment on urban tick control [<xref rid="B47-vaccines-13-00136" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00136" ref-type="bibr">48</xref>].</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00136"><title>5. Conclusions</title><p>Results of the immunization and tick challenge trials indicate that all antigen formulations were safe for the hosts; four of them induced a humoral response with increased levels of antigen-specific IgG and three of the formulations achieved more than 99% vaccine efficacy in mice. In general, tick feeding parameters were not affected by the vaccinations, and the final weight was reduced only slightly in some groups of larvae and nymphs. However, the larvae and nymph viability after feeding, the egg production by females, and the percentage of eggs that hatched were considerably affected and were the tick parameters that contributed most to the vaccines&#x02019; efficacy. Efficacies obtained in the present work, in addition to previous results with the same antigens [<xref rid="B17-vaccines-13-00136" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00136" ref-type="bibr">18</xref>], indicate that the best vaccine formulation was the combination of rAs8.9kDa and rAsChimera, and this formulation should be applied in further studies to produce a viable vaccine against <italic toggle="yes">A. sculptum</italic>.</p></sec><sec id="sec6-vaccines-13-00136"><title>6. Patents</title><p>Patents resulting from the work reported in this manuscript: BR 13 2024 006304 9.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Marcia G. Campos for maintaining the <italic toggle="yes">A. sculptum</italic> colony and providing the ticks used in the experiments.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00136"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines13020136/s1">https://www.mdpi.com/article/10.3390/vaccines13020136/s1</uri>, Figure S1. Representative dot plots illustrating the immunophenotyping analysis in peripheral blood from mice; Table S1. Kidney and liver function of mice immunized with rAs8.9kDa (8.9), rAsBasicTail (BT), rAsKunitz (Kn), and rAsChimera (Ch) combinations; Table S2. Hematological parameters of mice immunized with rAs8.9kDa (8.9), rAsBasicTail (BT), rAsKunitz (Kn), and rAsChimera (Ch) combinations.</p><supplementary-material id="vaccines-13-00136-s001" position="float" content-type="local-data"><media xlink:href="vaccines-13-00136-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, R.N.A., R.C.G., M.R.V.S., N.F.G. and M.H.P.; methodology, U.A.N., J.F.A., I.C.T.R., A.V.S. and H.S.R.; formal analysis, R.N.A., U.A.N., J.F.A., A.A.P.F., R.C.G., M.R.V.S., N.F.G. and M.H.P.; investigation, U.A.N., J.F.A., I.C.T.R., A.A.P.F., A.V.S. and H.S.R.; resources, R.N.A., R.C.G., M.R.V.S., N.F.G. and M.H.P.; data curation, R.N.A., U.A.N., J.F.A., I.C.T.R. and A.A.P.F.; writing&#x02014;original draft preparation, R.N.A., U.A.N., J.F.A. and A.A.P.F.; writing&#x02014;review and editing, R.N.A., U.A.N., J.F.A. and A.A.P.F.; supervision, R.N.A. and A.A.P.F.; project administration, R.N.A.; funding acquisition, R.N.A., M.R.V.S., N.F.G., M.H.P. and R.C.G. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The Ethics Committee on the Use of Animals (CEUA) from the Universidade Federal de Minas Gerais (UFMG) approved the maintenance of our tick colony and the vaccine experiments under the protocols 06/2020 and 103/2017.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data generated during the current study are available upon request to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00136"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Estrada-Pe&#x000f1;a</surname><given-names>A.</given-names></name>
<name><surname>Guglielmone</surname><given-names>A.A.</given-names></name>
<name><surname>Mangold</surname><given-names>A.J.</given-names></name>
</person-group><article-title>The Distribution and Ecological &#x0201c;preferences&#x0201d; of the Tick <italic toggle="yes">Amblyomma Cajennense</italic> (Acari: Ixodidae), an Ectoparasite of Humans and Other Mammals in the Americas</article-title><source>Ann. Trop. Med. Parasitol.</source><year>2004</year><volume>98</volume><fpage>283</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1179/000349804225003316</pub-id><pub-id pub-id-type="pmid">15119974</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00136"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guglielmone</surname><given-names>A.A.</given-names></name>
<name><surname>Beati</surname><given-names>L.</given-names></name>
<name><surname>Barros-Battesti</surname><given-names>D.M.</given-names></name>
<name><surname>Labruna</surname><given-names>M.B.</given-names></name>
<name><surname>Nava</surname><given-names>S.</given-names></name>
<name><surname>Venzal</surname><given-names>J.M.</given-names></name>
<name><surname>Mangold</surname><given-names>A.J.</given-names></name>
<name><surname>Szab&#x000f3;</surname><given-names>M.P.J.</given-names></name>
<name><surname>Martins</surname><given-names>J.R.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Acu&#x000f1;a</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Ticks (Ixodidae) on Humans in South America</article-title><source>Exp. Appl. Acarol.</source><year>2006</year><volume>40</volume><fpage>83</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1007/s10493-006-9027-0</pub-id><pub-id pub-id-type="pmid">17103085</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00136"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martins</surname><given-names>T.F.</given-names></name>
<name><surname>Barbieri</surname><given-names>A.R.M.</given-names></name>
<name><surname>Costa</surname><given-names>F.B.</given-names></name>
<name><surname>Terassini</surname><given-names>F.A.</given-names></name>
<name><surname>Camargo</surname><given-names>L.M.A.</given-names></name>
<name><surname>Peterka</surname><given-names>C.R.L.</given-names></name>
<name><surname>De</surname><given-names>C.</given-names></name>
<name><surname>Pacheco</surname><given-names>R.</given-names></name>
<name><surname>Dias</surname><given-names>R.A.</given-names></name>
<name><surname>Nunes</surname><given-names>P.H.</given-names></name>
<etal/>
</person-group><article-title>Geographical Distribution of Amblyomma Cajennense (Sensu Lato) Ticks (Parasitiformes: Ixodidae) in Brazil, with Description of the Nymph of A. Cajennense (Sensu Stricto)</article-title><source>Parasit. Vectors</source><year>2016</year><volume>9</volume><fpage>186</fpage><pub-id pub-id-type="doi">10.1186/s13071-016-1460-2</pub-id><pub-id pub-id-type="pmid">27036324</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00136"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szab&#x000f3;</surname><given-names>M.P.J.</given-names></name>
<name><surname>Martins</surname><given-names>T.F.</given-names></name>
<name><surname>Barbieri</surname><given-names>A.R.M.</given-names></name>
<name><surname>Costa</surname><given-names>F.B.</given-names></name>
<name><surname>Soares</surname><given-names>H.S.</given-names></name>
<name><surname>Tolesano-Pascoli</surname><given-names>G.V.</given-names></name>
<name><surname>Torga</surname><given-names>K.</given-names></name>
<name><surname>Saraiva</surname><given-names>D.G.</given-names></name>
<name><surname>Ramos</surname><given-names>V.D.N.</given-names></name>
<name><surname>Osava</surname><given-names>C.F.</given-names></name>
<etal/>
</person-group><article-title>Ticks Biting Humans in the Brazilian Savannah: Attachment Sites and Exposure Risk in Relation to Species, Life Stage and Season</article-title><source>Ticks Tick-Borne Dis.</source><year>2020</year><volume>11</volume><fpage>101328</fpage><pub-id pub-id-type="doi">10.1016/j.ttbdis.2019.101328</pub-id><pub-id pub-id-type="pmid">31767495</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00136"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Labruna</surname><given-names>M.B.</given-names></name>
<name><surname>Krawczak</surname><given-names>F.S.</given-names></name>
<name><surname>Gerardi</surname><given-names>M.</given-names></name>
<name><surname>Binder</surname><given-names>L.C.</given-names></name>
<name><surname>Barbieri</surname><given-names>A.R.M.</given-names></name>
<name><surname>Paz</surname><given-names>G.F.</given-names></name>
<name><surname>Rodrigues</surname><given-names>D.S.</given-names></name>
<name><surname>Ara&#x000fa;jo</surname><given-names>R.N.</given-names></name>
<name><surname>Bernardes</surname><given-names>M.L.</given-names></name>
<name><surname>Leite</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Isolation of Rickettsia Rickettsii from the Tick Amblyomma Sculptum from a Brazilian Spotted Fever-Endemic Area in the Pampulha Lake Region, Southeastern Brazil</article-title><source>Vet. Parasitol. Reg. Stud. Rep.</source><year>2017</year><volume>8</volume><fpage>82</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.vprsr.2017.02.007</pub-id><pub-id pub-id-type="pmid">31014644</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00136"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szab&#x000f3;</surname><given-names>M.P.J.</given-names></name>
<name><surname>Pinter</surname><given-names>A.</given-names></name>
<name><surname>Labruna</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Ecology, Biology and Distribution of Spotted-Fever Tick Vectors in Brazil</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2013</year><volume>3</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2013.00027</pub-id><pub-id pub-id-type="pmid">23875178</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00136"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Paula</surname><given-names>L.G.F.</given-names></name>
<name><surname>Do Nascimento</surname><given-names>R.M.</given-names></name>
<name><surname>Franco</surname><given-names>A.D.O.</given-names></name>
<name><surname>Szab&#x000f3;</surname><given-names>M.P.J.</given-names></name>
<name><surname>Labruna</surname><given-names>M.B.</given-names></name>
<name><surname>Monteiro</surname><given-names>C.</given-names></name>
<name><surname>Krawczak</surname><given-names>F.D.S.</given-names></name>
</person-group><article-title>Seasonal Dynamics of Amblyomma Sculptum: A Review</article-title><source>Parasit. Vectors</source><year>2022</year><volume>15</volume><fpage>193</fpage><pub-id pub-id-type="doi">10.1186/s13071-022-05311-w</pub-id><pub-id pub-id-type="pmid">35668507</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00136"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerardi</surname><given-names>M.</given-names></name>
<name><surname>Ram&#x000ed;rez-Hern&#x000e1;ndez</surname><given-names>A.</given-names></name>
<name><surname>Binder</surname><given-names>L.C.</given-names></name>
<name><surname>Krawczak</surname><given-names>F.S.</given-names></name>
<name><surname>Gregori</surname><given-names>F.</given-names></name>
<name><surname>Labruna</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Comparative Susceptibility of Different Populations of Amblyomma Sculptum to Rickettsia Rickettsii</article-title><source>Front. Physiol.</source><year>2019</year><volume>10</volume><elocation-id>653</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2019.00653</pub-id><pub-id pub-id-type="pmid">31191350</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00136"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karasek</surname><given-names>I.</given-names></name>
<name><surname>Butler</surname><given-names>C.</given-names></name>
<name><surname>Baynes</surname><given-names>R.</given-names></name>
<name><surname>Werners</surname><given-names>A.</given-names></name>
</person-group><article-title>A Review on the Treatment and Control of Ectoparasite Infestations in Equids</article-title><source>J. Vet. Pharmacol. Ther.</source><year>2020</year><volume>43</volume><fpage>421</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1111/jvp.12874</pub-id><pub-id pub-id-type="pmid">32488977</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00136"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Labruna</surname><given-names>M.B.</given-names></name>
<name><surname>Leite</surname><given-names>R.C.</given-names></name>
<name><surname>Gobesso</surname><given-names>A.A.D.O.</given-names></name>
<name><surname>Gennari</surname><given-names>S.M.</given-names></name>
<name><surname>Kasai</surname><given-names>N.</given-names></name>
</person-group><article-title>Controle estrat&#x000e9;gico do carrapato Amblyomma cajennense em eq&#x000fc;inos</article-title><source>Ci&#x000ea;nc. Rural</source><year>2004</year><volume>34</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1590/S0103-84782004000100030</pub-id></element-citation></ref><ref id="B11-vaccines-13-00136"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Welsh</surname><given-names>J.A.</given-names></name>
<name><surname>Braun</surname><given-names>H.</given-names></name>
<name><surname>Brown</surname><given-names>N.</given-names></name>
<name><surname>Um</surname><given-names>C.</given-names></name>
<name><surname>Ehret</surname><given-names>K.</given-names></name>
<name><surname>Figueroa</surname><given-names>J.</given-names></name>
<name><surname>Boyd Barr</surname><given-names>D.</given-names></name>
</person-group><article-title>Production-Related Contaminants (Pesticides, Antibiotics and Hormones) in Organic and Conventionally Produced Milk Samples Sold in the USA</article-title><source>Public Health Nutr.</source><year>2019</year><volume>22</volume><fpage>2972</fpage><lpage>2980</lpage><pub-id pub-id-type="doi">10.1017/S136898001900106X</pub-id><pub-id pub-id-type="pmid">31238996</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00136"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cardoso</surname><given-names>E.R.N.</given-names></name>
<name><surname>Carvalho</surname><given-names>S.F.</given-names></name>
<name><surname>Dias</surname><given-names>S.A.</given-names></name>
<name><surname>Santos</surname><given-names>R.A.</given-names></name>
<name><surname>Tavares</surname><given-names>M.A.</given-names></name>
<name><surname>Neves</surname><given-names>L.C.</given-names></name>
<name><surname>Paula</surname><given-names>W.V.D.F.</given-names></name>
<name><surname>P&#x000e1;dua</surname><given-names>G.T.</given-names></name>
<name><surname>De Lima</surname><given-names>N.J.</given-names></name>
<name><surname>Paludo</surname><given-names>R.L.D.R.</given-names></name>
<etal/>
</person-group><article-title>Susceptibility of Amblyomma Sculptum, Vector of Rickettsia Rickettsii, Ticks from a National Park and an Experimental Farm to Different Synthetic Acaricides</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>1304</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12111304</pub-id><pub-id pub-id-type="pmid">38003769</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00136"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza Freitas</surname><given-names>E.D.P.E.</given-names></name>
<name><surname>Zapata</surname><given-names>M.T.A.G.</given-names></name>
<name><surname>Fernandes</surname><given-names>F.D.F.</given-names></name>
</person-group><article-title>Monitoring of Resistance or Susceptibility of Adults and Larvae of Amblyomma Cajennense (Acari: Ixodidae) to Synthetic Acaricides in Goi&#x000e1;s, Brazil</article-title><source>Exp. Appl. Acarol.</source><year>2011</year><volume>53</volume><fpage>189</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1007/s10493-010-9389-1</pub-id><pub-id pub-id-type="pmid">20976616</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00136"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodr&#x000ed;guez-Valle</surname><given-names>M.</given-names></name>
<name><surname>Taoufik</surname><given-names>A.</given-names></name>
<name><surname>Vald&#x000e9;s</surname><given-names>M.</given-names></name>
<name><surname>Montero</surname><given-names>C.</given-names></name>
<name><surname>Hassan</surname><given-names>I.</given-names></name>
<name><surname>Hassan</surname><given-names>S.M.</given-names></name>
<name><surname>Jongejan</surname><given-names>F.</given-names></name>
<name><surname>De La Fuente</surname><given-names>J.</given-names></name>
</person-group><article-title>Efficacy of Rhipicephalus (Boophilus) Microplus Bm86 against Hyalomma Dromedarii and Amblyomma Cajennense Tick Infestations in Camels and Cattle</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>3453</fpage><lpage>3458</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.03.020</pub-id><pub-id pub-id-type="pmid">22446633</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00136"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodr&#x000ed;guez-Mallon</surname><given-names>A.</given-names></name>
<name><surname>Encinosa Guzm&#x000e1;n</surname><given-names>P.E.</given-names></name>
<name><surname>Bello Soto</surname><given-names>Y.</given-names></name>
<name><surname>Rosales Perdomo</surname><given-names>K.</given-names></name>
<name><surname>Montero Espinosa</surname><given-names>C.</given-names></name>
<name><surname>Vargas</surname><given-names>M.</given-names></name>
<name><surname>Estrada Garc&#x000ed;a</surname><given-names>M.P.</given-names></name>
</person-group><article-title>A Chemical Conjugate of the Tick P0 Peptide Is Efficacious against <italic toggle="yes">Amblyomma Mixtum</italic></article-title><source>Transbound. Emerg. Dis.</source><year>2020</year><volume>67</volume><fpage>175</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1111/tbed.13455</pub-id><pub-id pub-id-type="pmid">31975511</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00136"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nassar</surname><given-names>M.</given-names></name>
<name><surname>Martins</surname><given-names>L.A.</given-names></name>
<name><surname>De Assis</surname><given-names>J.B.</given-names></name>
<name><surname>Esteves</surname><given-names>E.</given-names></name>
<name><surname>S&#x000e1;-Nunes</surname><given-names>A.</given-names></name>
<name><surname>Labruna</surname><given-names>M.B.</given-names></name>
<name><surname>Daffre</surname><given-names>S.</given-names></name>
<name><surname>Foga&#x000e7;a</surname><given-names>A.C.</given-names></name>
</person-group><article-title>The Survival of Amblyomma Sculptum Ticks upon Blood-Feeding Depends on the Expression of an Inhibitor of Apoptosis Protein</article-title><source>Parasit. Vectors</source><year>2023</year><volume>16</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/s13071-023-05701-8</pub-id><pub-id pub-id-type="pmid">36899435</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00136"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa</surname><given-names>G.C.A.</given-names></name>
<name><surname>Ribeiro</surname><given-names>I.C.T.</given-names></name>
<name><surname>Melo-Junior</surname><given-names>O.</given-names></name>
<name><surname>Gontijo</surname><given-names>N.F.</given-names></name>
<name><surname>Sant&#x02019;Anna</surname><given-names>M.R.V.</given-names></name>
<name><surname>Pereira</surname><given-names>M.H.</given-names></name>
<name><surname>Pessoa</surname><given-names>G.C.D.</given-names></name>
<name><surname>Koerich</surname><given-names>L.B.</given-names></name>
<name><surname>Oliveira</surname><given-names>F.</given-names></name>
<name><surname>Valenzuela</surname><given-names>J.G.</given-names></name>
<etal/>
</person-group><article-title>Amblyomma Sculptum Salivary Protease Inhibitors as Potential Anti-Tick Vaccines</article-title><source>Front. Immunol.</source><year>2021</year><volume>11</volume><elocation-id>611104</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.611104</pub-id><pub-id pub-id-type="pmid">33633731</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00136"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa</surname><given-names>G.C.A.</given-names></name>
<name><surname>Ribeiro</surname><given-names>I.C.T.</given-names></name>
<name><surname>Giunchetti</surname><given-names>R.C.</given-names></name>
<name><surname>Gontijo</surname><given-names>N.F.</given-names></name>
<name><surname>Sant&#x02019;Anna</surname><given-names>M.R.V.</given-names></name>
<name><surname>Pereira</surname><given-names>M.H.</given-names></name>
<name><surname>Pessoa</surname><given-names>G.C.D.</given-names></name>
<name><surname>Koerich</surname><given-names>L.B.</given-names></name>
<name><surname>Oliveira</surname><given-names>F.</given-names></name>
<name><surname>Valenzuela</surname><given-names>J.G.</given-names></name>
<etal/>
</person-group><article-title>Gut Membrane Proteins as Candidate Antigens for Immunization of Mice against the Tick Amblyomma Sculptum</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>126141</fpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.07.042</pub-id><pub-id pub-id-type="pmid">39033080</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00136"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wharton</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Tick-Borne Livestock Diseases and Their Vectors. 5. Acaricide Resistance and Alternative Methods of Tick Control</article-title><source>World Anim. Rev.</source><year>1976</year><volume>20</volume><fpage>8</fpage><lpage>15</lpage></element-citation></ref><ref id="B20-vaccines-13-00136"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jackson</surname><given-names>L.A.</given-names></name>
<name><surname>Opdebeeck</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Humoral Immune Responses of Hereford Cattle Vaccinated with Midgut Antigens of the Cattle Tick, <italic toggle="yes">Boophilus Microplus</italic></article-title><source>Parasite Immunol.</source><year>1990</year><volume>12</volume><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.1990.tb00943.x</pub-id><pub-id pub-id-type="pmid">2320378</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00136"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kemp</surname><given-names>D.H.</given-names></name>
<name><surname>Pearson</surname><given-names>R.D.</given-names></name>
<name><surname>Gough</surname><given-names>J.M.</given-names></name>
<name><surname>Willadsen</surname><given-names>P.</given-names></name>
</person-group><article-title>Vaccination against Boophilus Microplus: Localization of Antigens on Tick Gut Cells and Their Interaction with the Host Immune System</article-title><source>Exp. Appl. Acarol.</source><year>1989</year><volume>7</volume><fpage>43</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/BF01200452</pub-id><pub-id pub-id-type="pmid">2667918</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00136"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kemp</surname><given-names>D.H.</given-names></name>
<name><surname>Agbede</surname><given-names>R.I.S.</given-names></name>
<name><surname>Johnston</surname><given-names>L.A.Y.</given-names></name>
<name><surname>Gough</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Immunization of Cattle against Boophilus Microplus Using Extracts Derived from Adult Female Ticks: Feeding and Survival of the Parasite on Vaccinated Cattle</article-title><source>Int. J. Parasitol.</source><year>1986</year><volume>16</volume><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/0020-7519(86)90096-2</pub-id><pub-id pub-id-type="pmid">3721702</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00136"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>J.Y.M.</given-names></name>
<name><surname>Opdebeeck</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Protective Efficacy of Antigens Solubilized from Gut Membranes of the Cattle Tick, Boophilus Microplus</article-title><source>Immunology</source><year>1989</year><volume>66</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">15493278</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00136"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bouchard</surname><given-names>K.R.</given-names></name>
<name><surname>Wikel</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Care, Maintenance, and Experimental Infestation of Ticks in the Laboratory Setting</article-title><source>Biology of Disease Vectors</source><publisher-name>Academic Press</publisher-name><publisher-loc>Marquardt, WC, USA</publisher-loc><year>2005</year><fpage>705</fpage><lpage>712</lpage></element-citation></ref><ref id="B25-vaccines-13-00136"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bradford</surname><given-names>M.M.</given-names></name>
</person-group><article-title>A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding</article-title><source>Anal. Biochem.</source><year>1976</year><volume>72</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(76)90527-3</pub-id><pub-id pub-id-type="pmid">942051</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00136"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aguirre</surname><given-names>A.D.A.R.</given-names></name>
<name><surname>Garcia</surname><given-names>M.V.</given-names></name>
<name><surname>Szab&#x000f3;</surname><given-names>M.P.J.</given-names></name>
<name><surname>Barros</surname><given-names>J.C.</given-names></name>
<name><surname>Andreotti</surname><given-names>R.</given-names></name>
</person-group><article-title>Formula to Evaluate Efficacy of Vaccines and Systemic Substances against Three-Host Ticks</article-title><source>Int. J. Parasitol.</source><year>2015</year><volume>45</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2015.02.003</pub-id><pub-id pub-id-type="pmid">25765624</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00136"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barros</surname><given-names>V.C.</given-names></name>
<name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>J.G.</given-names></name>
<name><surname>Cadete</surname><given-names>A.M.</given-names></name>
<name><surname>Santos</surname><given-names>V.C.</given-names></name>
<name><surname>Cavalcante</surname><given-names>R.R.</given-names></name>
<name><surname>Ara&#x000fa;jo</surname><given-names>R.N.</given-names></name>
<name><surname>Pereira</surname><given-names>M.H.</given-names></name>
<name><surname>Gontijo</surname><given-names>N.F.</given-names></name>
</person-group><article-title>The Role of Salivary and Intestinal Complement System Inhibitors in the Midgut Protection of Triatomines and Mosquitoes</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e6047</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006047</pub-id><pub-id pub-id-type="pmid">19557176</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00136"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khattab</surname><given-names>A.</given-names></name>
<name><surname>Barroso</surname><given-names>M.</given-names></name>
<name><surname>Miettinen</surname><given-names>T.</given-names></name>
<name><surname>Meri</surname><given-names>S.</given-names></name>
</person-group><article-title>Anopheles Midgut Epithelium Evades Human Complement Activity by Capturing Factor H from the Blood Meal</article-title><source>PLoS Negl. Trop. Dis.</source><year>2015</year><volume>9</volume><elocation-id>e0003513</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003513</pub-id><pub-id pub-id-type="pmid">25679788</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00136"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lindblad</surname><given-names>E.B.</given-names></name>
</person-group><article-title>Aluminium Adjuvants&#x02014;In Retrospect and Prospect</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>3658</fpage><lpage>3668</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.03.032</pub-id><pub-id pub-id-type="pmid">15315845</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00136"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cunha</surname><given-names>R.C.</given-names></name>
<name><surname>Saimo-Kahwa</surname><given-names>M.</given-names></name>
<name><surname>Val&#x000e9;rio Garcia</surname><given-names>M.</given-names></name>
<name><surname>Santos</surname><given-names>F.D.S.</given-names></name>
<name><surname>Samuel</surname><given-names>E.</given-names></name>
<name><surname>Ann</surname><given-names>N.</given-names></name>
<name><surname>Ikwap</surname><given-names>K.</given-names></name>
<name><surname>Julie Akwongo</surname><given-names>C.</given-names></name>
<name><surname>Leivas Leite</surname><given-names>F.P.</given-names></name>
<name><surname>Andreotti</surname><given-names>R.</given-names></name>
</person-group><article-title>RA92A Recombinant Protein as Immunogen to Protect Cattle against Tick Challenge in Brazil and Uganda</article-title><source>Biosci. J.</source><year>2021</year><volume>37</volume><elocation-id>e37068</elocation-id><pub-id pub-id-type="doi">10.14393/BJ-v37n0a2021-49905</pub-id></element-citation></ref><ref id="B31-vaccines-13-00136"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitsou</surname><given-names>C.</given-names></name>
<name><surname>Fikrig</surname><given-names>E.</given-names></name>
<name><surname>Pal</surname><given-names>U.</given-names></name>
</person-group><article-title>Tick Host Immunity: Vector Immunomodulation and Acquired Tick Resistance</article-title><source>Trends Immunol.</source><year>2021</year><volume>42</volume><fpage>554</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.it.2021.05.005</pub-id><pub-id pub-id-type="pmid">34074602</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00136"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ndawula</surname><given-names>C.</given-names></name>
<name><surname>Tabor</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Cocktail Anti-Tick Vaccines: The Unforeseen Constraints and Approaches toward Enhanced Efficacies</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>457</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030457</pub-id><pub-id pub-id-type="pmid">32824962</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00136"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwarz</surname><given-names>H.</given-names></name>
<name><surname>Schmittner</surname><given-names>M.</given-names></name>
<name><surname>Duschl</surname><given-names>A.</given-names></name>
<name><surname>Horejs-Hoeck</surname><given-names>J.</given-names></name>
</person-group><article-title>Residual Endotoxin Contaminations in Recombinant Proteins Are Sufficient to Activate Human CD1c+ Dendritic Cells</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e113840</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0113840</pub-id><pub-id pub-id-type="pmid">25478795</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00136"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faber</surname><given-names>E.</given-names></name>
<name><surname>Tshilwane</surname><given-names>S.I.</given-names></name>
<name><surname>Van Kleef</surname><given-names>M.</given-names></name>
<name><surname>Pretorius</surname><given-names>A.</given-names></name>
</person-group><article-title>The Impact of Escherichia Coli Contamination Products Present in Recombinant African Horse Sickness Virus Serotype 4 Proteins on the Innate and Humoral Immune Responses</article-title><source>Mol. Immunol.</source><year>2022</year><volume>152</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2022.09.013</pub-id><pub-id pub-id-type="pmid">36215827</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00136"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>G.R.</given-names></name>
<name><surname>Maruyama</surname><given-names>S.R.</given-names></name>
<name><surname>Nelson</surname><given-names>K.T.</given-names></name>
<name><surname>Ribeiro</surname><given-names>J.M.C.</given-names></name>
<name><surname>Gardinassi</surname><given-names>L.G.</given-names></name>
<name><surname>Maia</surname><given-names>A.A.M.</given-names></name>
<name><surname>Ferreira</surname><given-names>B.R.</given-names></name>
<name><surname>Kooyman</surname><given-names>F.N.J.</given-names></name>
<name><surname>De Miranda Santos</surname><given-names>I.K.F.</given-names></name>
</person-group><article-title>Immune Recognition of Salivary Proteins from the Cattle Tick Rhipicephalus Microplus Differs According to the Genotype of the Bovine Host</article-title><source>Parasit. Vectors</source><year>2017</year><volume>10</volume><fpage>144</fpage><pub-id pub-id-type="doi">10.1186/s13071-017-2077-9</pub-id><pub-id pub-id-type="pmid">28288696</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00136"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antunes</surname><given-names>S.</given-names></name>
<name><surname>Domingos</surname><given-names>A.</given-names></name>
</person-group><article-title>Tick Vaccines and Concealed versus Exposed Antigens</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>374</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12030374</pub-id><pub-id pub-id-type="pmid">36986295</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00136"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Canales</surname><given-names>M.</given-names></name>
<name><surname>Enr&#x000ed;quez</surname><given-names>A.</given-names></name>
<name><surname>Ramos</surname><given-names>E.</given-names></name>
<name><surname>Cabrera</surname><given-names>D.</given-names></name>
<name><surname>Dandie</surname><given-names>H.</given-names></name>
<name><surname>Soto</surname><given-names>A.</given-names></name>
<name><surname>Falc&#x000f3;n</surname><given-names>V.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>M.</given-names></name>
<name><surname>De La Fuente</surname><given-names>J.</given-names></name>
</person-group><article-title>Large-Scale Production in Pichia Pastoris of the Recombinant Vaccine Gavac<sup>TM</sup> against Cattle Tick</article-title><source>Vaccine</source><year>1997</year><volume>15</volume><fpage>414</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(96)00192-2</pub-id><pub-id pub-id-type="pmid">9141213</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00136"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neuberger</surname><given-names>M.S.</given-names></name>
<name><surname>Rajewsky</surname><given-names>K.</given-names></name>
</person-group><article-title>Activation of Mouse Complement by Monoclonal Mouse Antibodies</article-title><source>Eur. J. Immunol.</source><year>1981</year><volume>11</volume><fpage>1012</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1002/eji.1830111212</pub-id><pub-id pub-id-type="pmid">7327198</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00136"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parthasarathi</surname><given-names>B.C.</given-names></name>
<name><surname>Kumar</surname><given-names>B.</given-names></name>
<name><surname>Bhure</surname><given-names>S.K.</given-names></name>
<name><surname>Sharma</surname><given-names>A.K.</given-names></name>
<name><surname>Manisha</surname></name>
<name><surname>Nagar</surname><given-names>G.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Nandi</surname><given-names>A.</given-names></name>
<name><surname>Manjunathachar</surname><given-names>H.V.</given-names></name>
<name><surname>Chigure</surname><given-names>G.M.</given-names></name>
<etal/>
</person-group><article-title>Co-Immunization Efficacy of Recombinant Antigens against Rhipicephalus Microplus and Hyalomma anatolicumTick Infestations</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>433</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12030433</pub-id><pub-id pub-id-type="pmid">36986356</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00136"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodr&#x000ed;guez-Dur&#x000e1;n</surname><given-names>A.</given-names></name>
<name><surname>Ullah</surname><given-names>S.</given-names></name>
<name><surname>Parizi</surname><given-names>L.F.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Da Silva Vaz Junior</surname><given-names>I.</given-names></name>
</person-group><article-title>Rabbits as Animal Models for Anti-Tick Vaccine Development: A Global Scenario</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>1117</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12091117</pub-id><pub-id pub-id-type="pmid">37764925</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00136"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Csordas</surname><given-names>B.G.</given-names></name>
<name><surname>Cunha</surname><given-names>R.C.</given-names></name>
<name><surname>Garcia</surname><given-names>M.V.</given-names></name>
<name><surname>da Silva</surname><given-names>S.S.</given-names></name>
<name><surname>Leite</surname><given-names>F.L.</given-names></name>
<name><surname>Andreotti</surname><given-names>R.</given-names></name>
</person-group><article-title>Molecular Characterization of the Recombinant Protein RmLTI-BmCG-LTB: Protective Immunity against Rhipicephalus (Boophilus) Microplus</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0191596</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0191596</pub-id><pub-id pub-id-type="pmid">29415034</pub-id>
</element-citation></ref><ref id="B42-vaccines-13-00136"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De La Fuente</surname><given-names>J.</given-names></name>
<name><surname>Manzano-Roman</surname><given-names>R.</given-names></name>
<name><surname>Naranjo</surname><given-names>V.</given-names></name>
<name><surname>Kocan</surname><given-names>K.M.</given-names></name>
<name><surname>Zivkovic</surname><given-names>Z.</given-names></name>
<name><surname>Blouin</surname><given-names>E.F.</given-names></name>
<name><surname>Canales</surname><given-names>M.</given-names></name>
<name><surname>Almaz&#x000e1;n</surname><given-names>C.</given-names></name>
<name><surname>Galindo</surname><given-names>R.C.</given-names></name>
<name><surname>Step</surname><given-names>D.L.</given-names></name>
<etal/>
</person-group><article-title>Identification of Protective Antigens by RNA Interference for Control of the Lone Star Tick, Amblyomma Americanum</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>1786</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.12.007</pub-id><pub-id pub-id-type="pmid">20018267</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00136"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de la Fuente</surname><given-names>J.</given-names></name>
<name><surname>Contreras</surname><given-names>M.</given-names></name>
</person-group><article-title>Tick Vaccines: Current Status and Future Directions</article-title><source>Expert Rev. Vaccines</source><year>2015</year><volume>14</volume><fpage>1367</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.1076339</pub-id><pub-id pub-id-type="pmid">26289976</pub-id>
</element-citation></ref><ref id="B44-vaccines-13-00136"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guerrero</surname><given-names>F.D.</given-names></name>
<name><surname>Miller</surname><given-names>R.J.</given-names></name>
<name><surname>P&#x000e9;rez De Le&#x000f3;n</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Cattle Tick Vaccines: Many Candidate Antigens, but Will a Commercially Viable Product Emerge?</article-title><source>Int. J. Parasitol.</source><year>2012</year><volume>42</volume><fpage>421</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2012.04.003</pub-id><pub-id pub-id-type="pmid">22549026</pub-id>
</element-citation></ref><ref id="B45-vaccines-13-00136"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kasaija</surname><given-names>P.D.</given-names></name>
<name><surname>Contreras</surname><given-names>M.</given-names></name>
<name><surname>Kabi</surname><given-names>F.</given-names></name>
<name><surname>Mugerwa</surname><given-names>S.</given-names></name>
<name><surname>De La Fuente</surname><given-names>J.D.L.</given-names></name>
</person-group><article-title>Vaccination with Recombinant Subolesin Antigens Provides Cross-Tick Species Protection in Bos Indicus and Crossbred Cattle in Uganda</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>319</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020319</pub-id><pub-id pub-id-type="pmid">32570925</pub-id>
</element-citation></ref><ref id="B46-vaccines-13-00136"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maruyama</surname><given-names>S.R.</given-names></name>
<name><surname>Garcia</surname><given-names>G.R.</given-names></name>
<name><surname>Teixeira</surname><given-names>F.R.</given-names></name>
<name><surname>Brand&#x000e3;o</surname><given-names>L.G.</given-names></name>
<name><surname>Anderson</surname><given-names>J.M.</given-names></name>
<name><surname>Ribeiro</surname><given-names>J.M.C.</given-names></name>
<name><surname>Valenzuela</surname><given-names>J.G.</given-names></name>
<name><surname>Horackova</surname><given-names>J.</given-names></name>
<name><surname>Ver&#x000ed;ssimo</surname><given-names>C.J.</given-names></name>
<name><surname>Katiki</surname><given-names>L.M.</given-names></name>
<etal/>
</person-group><article-title>Mining a Differential Sialotranscriptome of Rhipicephalus Microplus Guides Antigen Discovery to Formulate a Vaccine That Reduces Tick Infestations</article-title><source>Parasit. Vectors</source><year>2017</year><volume>10</volume><fpage>206</fpage><pub-id pub-id-type="doi">10.1186/s13071-017-2136-2</pub-id><pub-id pub-id-type="pmid">28446245</pub-id>
</element-citation></ref><ref id="B47-vaccines-13-00136"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luz</surname><given-names>H.R.</given-names></name>
<name><surname>Costa</surname><given-names>F.B.</given-names></name>
<name><surname>Benatti</surname><given-names>H.R.</given-names></name>
<name><surname>Ramos</surname><given-names>V.N.</given-names></name>
<name><surname>De</surname><given-names>A.</given-names></name>
<name><surname>Serpa</surname><given-names>M.C.</given-names></name>
<name><surname>Martins</surname><given-names>T.F.</given-names></name>
<name><surname>Acosta</surname><given-names>I.C.L.</given-names></name>
<name><surname>Ramirez</surname><given-names>D.G.</given-names></name>
<name><surname>Mu&#x000f1;oz-Leal</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Epidemiology of Capybara-Associated Brazilian Spotted Fever</article-title><source>PLoS Negl. Trop. Dis.</source><year>2019</year><volume>13</volume><elocation-id>e0007734</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0007734</pub-id><pub-id pub-id-type="pmid">31490924</pub-id>
</element-citation></ref><ref id="B48-vaccines-13-00136"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szab&#x000f3;</surname><given-names>M.P.J.</given-names></name>
<name><surname>Queiroz</surname><given-names>C.L.</given-names></name>
<name><surname>Suzin</surname><given-names>A.</given-names></name>
<name><surname>Rodrigues</surname><given-names>V.D.S.</given-names></name>
<name><surname>Vieira</surname><given-names>R.B.K.</given-names></name>
<name><surname>Martins</surname><given-names>M.M.</given-names></name>
<name><surname>Rezende</surname><given-names>L.M.</given-names></name>
<name><surname>Sousa</surname><given-names>A.C.P.</given-names></name>
<name><surname>Ramos</surname><given-names>V.D.N.</given-names></name>
<name><surname>Muraro</surname><given-names>F.M.</given-names></name>
<etal/>
</person-group><article-title>Density and Behavior of Capybara (Hydrochoerus Hydrochaeris) Ticks (Acari: Ixodidae) Amblyomma Sculptum and Amblyomma Dubitatum with Notes on Rickettsia Bellii Infection: Assessing Human Exposure Risk</article-title><source>Ticks Tick-Borne Dis.</source><year>2024</year><volume>15</volume><fpage>102330</fpage><pub-id pub-id-type="doi">10.1016/j.ttbdis.2024.102330</pub-id><pub-id pub-id-type="pmid">38460340</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00136-f001"><label>Figure 1</label><caption><p>Schematic diagram of the immunization, blood collections, and tick challenge.</p></caption><graphic xlink:href="vaccines-13-00136-g001" position="float"/></fig><fig position="float" id="vaccines-13-00136-f002"><label>Figure 2</label><caption><p>Comparative analysis of leukocytes by flow cytometry using whole blood before immunization (D-2) and 12 days after the last dose (D40) in the control (Ct) and vaccinated (V1&#x02013;V5) groups. The leukocytes evaluated were CD4<sup>+</sup>CD3<sup>+</sup> (<bold>A</bold>), CD8<sup>+</sup>CD3<sup>+</sup> (<bold>B</bold>), and CD14<sup>+</sup> (<bold>C</bold>), and CD14<sup>+</sup> (<bold>D</bold>). The vaccine formulations contained the antigens rAs8.9kDa (8.9), rAsBasicTail (BT), rAsKunitz (Kn), and rAsChimera (Chi). Experimental groups: Ct&#x02014;control (adjuvant); V1&#x02014;8.9+Chi; V2&#x02014;Bt+Ch; V3&#x02014;Kun+Ch; V4&#x02014;Kun+8.9+Ch; V5&#x02014;Kun+Bt+8.9+Ch. Data are shown as mean &#x000b1; SD. Blood samples collected from five animals in each group were used in the analysis. Statistical analysis: ANOVA and Tukey&#x02019;s multiple comparison test; different letters indicate a significant difference (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="vaccines-13-00136-g002" position="float"/></fig><fig position="float" id="vaccines-13-00136-f003"><label>Figure 3</label><caption><p>Humoral response produced against the antigens used for the immunization of mice. Total IgG levels were measured by ELISA; plates were sensitized with all four antigens combined (rAs8.9kDa (8.9), rAsBasicTail (BT), rAsKunitz (Kn), and rAsChimera (Ch)). Experimental groups: Ct&#x02014;control (adjuvant); V1&#x02014;8.9+Chi; V2&#x02014;Bt+Ch; V3&#x02014;Kun+Ch; V4&#x02014;Kun+8.9+Ch; and V5&#x02014;Kun+Bt+8.9+Ch. Data are represented by mean &#x000b1; SE. Blood collected from 13 animals in each group was used in the analysis. Statistical analysis: two-way ANOVA and Dunnett&#x02019;s multiple comparison test; asterisks indicate a significant difference compared to Ct (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="vaccines-13-00136-g003" position="float"/></fig><fig position="float" id="vaccines-13-00136-f004"><label>Figure 4</label><caption><p>Antigen-specific IgG levels of mice immunized with the rAsKunitz, rAs8.9kDa, rAsBasicTail, and AsChimera combinations. Total IgG levels were measured by ELISA; plates were sensitized with the four antigens individually as follows: (<bold>A</bold>) rAsKunitz (Kn), (<bold>B</bold>) rAs8.9kDa (8.9), (<bold>C</bold>) rAsBasicTail (BT), and (<bold>D</bold>) rAsChimera (Ch). Experimental groups: Ct&#x02014;control (adjuvant); V1&#x02014;8.9+Chi; V2&#x02014;Bt+Ch; V3&#x02014;Kun+Ch; V4&#x02014;Kun+8.9+Ch; and V5&#x02014;Kun+Bt+8.9+Ch. Data are represented by mean &#x000b1; SE. Blood collected from five animals in each group was used in the analysis. Statistical analysis: two-way ANOVA and Dunnet&#x02019;s multiple comparison test; asterisks indicate significant differences compared to the control (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="vaccines-13-00136-g004" position="float"/></fig><fig position="float" id="vaccines-13-00136-f005"><label>Figure 5</label><caption><p>Feeding period and final weight of <italic toggle="yes">A. sculptum</italic> fed on mice immunized with the antigens rAs8.9kDa (8.9), rAsBasicTail (BT), rAsKunitz (Kn), and AsChimera (Ch). Parameters were measured from larvae (<bold>A</bold>,<bold>D</bold>), nymphs (<bold>B</bold>,<bold>E</bold>) and females (<bold>C</bold>,<bold>F</bold>). Experimental groups: Ct&#x02014;control (adjuvant); V1&#x02014;8.9+Ch; V2&#x02014;Bt+Ch; V3&#x02014;Kn+Ch; V4&#x02014;Kn+8.9+Ch; and V5&#x02014;Kn+Bt+8.9+Ch. Data are shown as mean &#x000b1; SD. Statistical analysis: Kruskal&#x02013;Wallis test and Dunn&#x02019;s post-test; asterisks indicate significant differences to the control: * <italic toggle="yes">p</italic> &#x0003c; 0.05, *** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="vaccines-13-00136-g005" position="float"/></fig><fig position="float" id="vaccines-13-00136-f006"><label>Figure 6</label><caption><p>Reproductive parameters of <italic toggle="yes">A. sculptum</italic> females fed on mice immunized with rAs8.9kDa (8.9), rAsBasicTail (BT), rAsKunitz (Kn), and AsChimera (Ch) combinations. Reproductive parameters: (<bold>A</bold>) egg mass laid by females and (<bold>B</bold>) percent of hatching larvae. Experimental groups: Ct&#x02014;control (adjuvant); V1&#x02014;8.9+Ch; V2&#x02014;Bt+Ch; V3&#x02014;Kun+Ch; V4&#x02014;Kun+8.9+Ch; V5&#x02014;Kun+Bt+8.9+Ch. Data are shown as mean &#x000b1; SD. Statistical analysis: one-way ANOVA and Dunn&#x02019;s multiple comparison test; no significant differences were observed between groups.</p></caption><graphic xlink:href="vaccines-13-00136-g006" position="float"/></fig><table-wrap position="float" id="vaccines-13-00136-t001"><object-id pub-id-type="pii">vaccines-13-00136-t001_Table 1</object-id><label>Table 1</label><caption><p>Feeding, development and reproductive parameters of <italic toggle="yes">A. sculptum</italic> fed on mice previously immunized with the rAs8.9kDa (8.9), rAsBasicTail (BT), rAsKunitz (Kn), and rAsChimera (Ch) combinations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th><th align="right" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Groups</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Ct<break/>(Control)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">V1<break/>(8.9Ch)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">V2<break/>(BtCh)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">V3<break/>(KnCh)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">V4<break/>(Kn8.9Ch)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">V5<break/>(KnBt8.9Ch)</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td colspan="2" align="left" valign="middle" rowspan="1">Larvae</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Fed (%) <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">98.0</td><td align="center" valign="middle" rowspan="1" colspan="1">66.4</td><td align="center" valign="middle" rowspan="1" colspan="1">71.6</td><td align="center" valign="middle" rowspan="1" colspan="1">82.6</td><td align="center" valign="middle" rowspan="1" colspan="1">93.8</td><td align="center" valign="middle" rowspan="1" colspan="1">97.5</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Molted (%) <sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">95.0</td><td align="center" valign="middle" rowspan="1" colspan="1">13.3</td><td align="center" valign="middle" rowspan="1" colspan="1">16.1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.0</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td><td align="center" valign="middle" rowspan="1" colspan="1">59.9</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Mortality (%) <sup>3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6.9</td><td align="center" valign="middle" rowspan="1" colspan="1">91.9</td><td align="center" valign="middle" rowspan="1" colspan="1">88.4</td><td align="center" valign="middle" rowspan="1" colspan="1">87.8</td><td align="center" valign="middle" rowspan="1" colspan="1">53.1</td><td align="center" valign="middle" rowspan="1" colspan="1">41.6</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Nymphs</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Fed (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">84.6</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">97.5</td><td align="center" valign="middle" rowspan="1" colspan="1">97.2</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Molted (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">9.1</td><td align="center" valign="middle" rowspan="1" colspan="1">16.3</td><td align="center" valign="middle" rowspan="1" colspan="1">17.8</td><td align="center" valign="middle" rowspan="1" colspan="1">87.2</td><td align="center" valign="middle" rowspan="1" colspan="1">97.1</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Mortality (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">92.3</td><td align="center" valign="middle" rowspan="1" colspan="1">83.7</td><td align="center" valign="middle" rowspan="1" colspan="1">82.2</td><td align="center" valign="middle" rowspan="1" colspan="1">15.0</td><td align="center" valign="middle" rowspan="1" colspan="1">5.6</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Females</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Fed (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">66.7</td><td align="center" valign="middle" rowspan="1" colspan="1">88.9</td><td align="center" valign="middle" rowspan="1" colspan="1">80.0</td><td align="center" valign="middle" rowspan="1" colspan="1">70.0</td><td align="center" valign="middle" rowspan="1" colspan="1">90.0</td></tr><tr><td colspan="2" align="left" valign="middle" rowspan="1">Fertile (%) <sup>4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">50.0</td><td align="center" valign="middle" rowspan="1" colspan="1">87.5</td><td align="center" valign="middle" rowspan="1" colspan="1">87.5</td><td align="center" valign="middle" rowspan="1" colspan="1">85.7</td><td align="center" valign="middle" rowspan="1" colspan="1">55.6</td></tr><tr><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">Unfed+infertile (%) <sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.0</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Percentage of fed ticks recovered from immunized mice; <sup>2</sup> percentage of molted ticks within the fed ticks recovered; <sup>3</sup> overall mortality during or after feeding; <sup>4</sup> percentage of fed females that laid eggs; <sup>5</sup> percentage of unfed females and fed but infertile females.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00136-t002"><object-id pub-id-type="pii">vaccines-13-00136-t002_Table 2</object-id><label>Table 2</label><caption><p>Vaccine efficacy based on mortality, development, and reproductive parameters in larvae, nymphs, and females fed on mice previously immunized with the rAs8.9kDa (8.9), rAsBasicTail (BT), rAsKunitz (Kn), and rAsChimera (Ch) combinations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Groups <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">VL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RN</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">VN</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FE</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">E (%) <sup>2</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ct (Control)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V1 (8.9Ch)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.68</td><td align="center" valign="middle" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85</td><td align="center" valign="middle" rowspan="1" colspan="1">0.09</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" rowspan="1" colspan="1">99.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V2 (BtCh)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56</td><td align="center" valign="middle" rowspan="1" colspan="1">99.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 (KnCh)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76</td><td align="center" valign="middle" rowspan="1" colspan="1">99.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V4 (Kn8.9Ch)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98</td><td align="center" valign="middle" rowspan="1" colspan="1">0.87</td><td align="center" valign="middle" rowspan="1" colspan="1">0.70</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" rowspan="1" colspan="1">91.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V5 (KnBt8.9Ch)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.6</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Experimental groups (antigen combination); <sup>2</sup> vaccine efficacy (E) was calculated according to Aguirre et al. [<xref rid="B26-vaccines-13-00136" ref-type="bibr">26</xref>], where E(%) = 100 &#x000d7; [1 &#x02212; (RL &#x000d7; VL &#x000d7; RN &#x000d7; VN &#x000d7; RA &#x000d7; OA &#x000d7; FE)], and RL is the effect of vaccination on larvae recovery = RLvaccinated/RLcontrol; RN is the effect of vaccination on nymph recovery = RNv/RNc; RA is the effect of vaccination on adult female recovery = RAv/Rac; VL is the effect on larvae viability = VLv/VLc; VN is the effect on nymph viability = VNv/VNc; OA is the effect on female oviposition, which is the ratio between the average weight of the egg mass laid by females in the vaccinated (OAv) and control (OAc) groups = OAv/OAc; and FE is the effect on egg fertility, which is the ratio between the average hatchability (%) of eggs laid by females in the vaccinated (FEv) and control (FEc) groups = FEv/FEc.</p></fn></table-wrap-foot></table-wrap></floats-group></article>